MedTrace Logo

Taper Or Abrupt Steroid Stop: TOASSTtrial

NCT03153527 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2026-04-22

No results posted yet for this study

Summary

This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.

Conditions

Interventions

DRUG

Prednisone

The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.

OTHER

Placebo Arm

The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.

Sponsors & Collaborators

  • Kantonsspital Baselland Bruderholz

    collaborator OTHER

  • Swiss National Science Foundation

    collaborator OTHER

  • HEMMI Stiftung Switzerland

    collaborator UNKNOWN

  • Gebauer Stiftung Zurich

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Jonas Rutishauser, Prof MD · Departement Medizin, Kantonsspital Baden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03153527 on ClinicalTrials.gov